Cancer Biomarkers and Oncoviruses

Herausgeber: Ennaji, Moulay Mustapha

• Broschiertes Buch

Produktbeschreibung

Cancer Biomarkers and Oncoviruses examines the extensive clinical applications of biomarkers in cancer research, with a particular focus on oncoviruses. The book explores key topics such as cancer risk assessment, screening, and early detection. It further covers accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring. In 47 detailed chapters, Cancer Biomarkers and Oncoviruses presents the molecular biology and pathogenesis of viral oncology, the mechanisms of viral oncogenesis in humans, signaling pathways, and therapeutic options such as vaccines. It also discusses the future of cancer therapy involving oncoviruses. The present book also covers critical analyses of cost savings in healthcare, respiratory biomarkers in viral infections, and lessons learned from the COVID-19 pandemic, focusing on pandemic preparedness, early detection, surveillance, and response strategies. These discussions aim to provide valuable insights into how lessons from the pandemic can be applied to improve healthcare systems and response strategies for both viral infections and cancer, helping inform future health management practices. This book is an invaluable resource for health professionals, scientists, researchers, health practitioners, students, and anyone seeking to deepen their understanding in the field of cancer and virology. It offers valuable state-of-the-art insights, incorporating the latest research and cutting-edge developments in the field.

Produktdetails

• Verlag: Elsevier Science
• Seitenzahl: 900
• Erscheinungstermin: 10. Dezember 2025
• Englisch
• Gewicht: 450g
• ISBN-13: 9780443302251
• ISBN-10: 0443302251
• Artikelnr.: 70071850

Inhaltsangabe

Part 1 Cancers: genetic insights, molecular mechanisms, and emerging
therapies
Chapter 1: Breast cancer and new methods for treatment
Chapter 2: The role of genetic markers P53, BRCA1, and BRCA2 in breast
cancer risk assessment in women
Chapter 3: MicroRNAs as key regulators of hormone dependent pathways in
breast cancer
Part 2 Lung and prostate cancer: genetic abnormalities and biomarkers
Chapter 4: Genetic abnormalities of the EGFR pathway in the Middle East and
North African patients with non-small cell lung cancer
Chapter 5: MicroRNAs: advances in biomarkers, diagnostics, and therapeutic
strategies in prostate cancer
Part 3 HPV and cervical cancer: screening, prevention, and molecular
mechanisms
Chapter 6: Human papillomavirus infections in cervical cells for cervical
cancer screening
Chapter 7: MicroRNA and human herpesvirus 8 oncovirus in prostate cancer
Part 4 Vitamin D and immune modulation in cancer
Chapter 8: Prostate cancer antigen 3 as a diagnostic, prognostic, and
therapeutic biomarker in prostate cancer
Chapter 9: Interaction of the vitamin D in cancer development and
progression
Part 5 Emerging therapies and biomarkers in cancer
Chapter 10: Study of the role of microRNAs in epstein barr virus induced
prostate carcinogenesis
Chapter 11: Addressing the burden of human papillomavirus-related cancers
in North Africa: epidemiology, sociocultural barriers and prevention
strategies
Part 6 Management of the COVID-19 pandemic: lessons learned, surveillance,
and respiratory biomarkers in SARS-CoV-2 pathogenesis
Chapter 12: Management of the COVID-19 pandemic in Skhirate-Temara,
Morocco: lessons in preparedness, surveillance, and rapid response
Chapter 13: Respiratory biomarkers in the pathogenesis of SARS-CoV-2
Part 7 Viral miRNAs and oncoviruses: diagnostic, prognostic biomarkers, and
therapeutic implications in cancer
Chapter 14: Oncoviruses and cancer biomarkers: current and future
perspectives
Chapter 15: MicroRNAs in cancer development: biomarkers, functions and
therapy
Chapter 16: Viral miRNA’s: unlocking new frontiers in virus-induced cancers
Part 8 Genetic and molecular basis of cancer
Chapter 17: Molecular alterations involved in lung cancer
Chapter 18: Oncogenic BRAF in prostate cancer: exosomes and miRNA status
and implications for targeted therapy
Chapter 19: Targeted therapy in prostate and bladder cancer-role of BRAF
and RAS mutations
Chapter 20: In-depth analysis of tumor markers in leukemia
Part 9 Molecular mechanisms and therapeutic implications in cancer
Chapter 21: Nasopharyngeal cancer associated with epstein barr virus
Chapter 22: Molecular mechanisms of cervical cancer
Part 10 Economic and market analysis in cancer research
Chapter 23: Critical analysis of the cost savings generated by biomarkers
and oncoviruses in healthcare
Chapter 24: Market analysis of exosome technologies for the diagnosis of
genitourinary cancers
Part 11 Phage therapy and immune modulation
Chapter 25: Phagotherapy: The discreet power of our immune cells
Part 12 Emerging therapies and biomarkers in cancer
Chapter 26: Mechanism of resistance to platinum salt-based chemotherapy
Chapter 27: Marine algae as a source of bioactive compounds: unlocking
anticancer potential
Chapter 28: Cervical cancer: new treatment approaches using microRNA
Chapter 29: Therapeutic potential of the intratumoral microbiota in tumors
Chapter 30: Molecular biomarkers in bladder cancer: identification and
clinical relevance
Chapter 31: Emerging biomarker applications for precision targeting in
bladder cancer therapy
Chapter 32: Fusion gene and cancer
Chapter 33: Immunotherapy biomarkers in melanoma: fromprogrammed
death-ligand 1 expression to tumor mutational burden
Chapter 34: The role of vitamin D supplementation in cancer treatment
Chapter 35: The role of vitamin D in modulating immune responses against
oncoviruses human papillomavirus, Epstein-Barr virus, and human
herpesvirus-8
Part 13 Epigenetics and DNA methylation in cancer
Chapter 36: Post-transcriptional epigenetic marks: DNA and microRNA
methylation
Chapter 37: Epigenetic mechanism induced by human herpesvirus 8 in prostate
cancer
Chapter 38: Role of methylation DNA in cell regulation
Chapter 39: DNA methylation biomarkers in colorectal cancer
Part 14 Oncoviruses and viral-associated cancers
Chapter 40: Deciphering the molecular tapestry: extracellular vesicles as
pioneering biomarker reservoirs for precision therapy in urogenital cancers
Chapter 41: Retroviruses as biomarkers in prostate carcinoma
Chapter 42: The role of breast cancer gene 1 and breast cancer gene 2 in
determining breast cancer therapy
Chapter 43: The biomarkers landscape in lung cancer: implication for
diagnosis, prediction, and prognosis
Chapter 44: Human papillomavirus as the main cause of cervical cancer:
diagnosis, treatment, and prevention
Chapter 45: Oncogenic role of proline-rich protein 11 in breast and
gynecologic cancers: mechanisms, signaling pathways, and therapeutic
implications
Chapter 46: MicroRNAs as biomarkers in gynecological-mammary cancers
Chapter 47: Proline-rich protein 11 as a diagnosis and prognosis biomarker
in breast and cervical cancers
Chapter 48: Recent advances in therapy and biomarkers: triple negative
breast cancer
Chapter 49: Recent advances in exosome-based therapies for prostate cancer:
targeting oncoviral and epigenetic pathways
Chapter 50: Exosomes as carriers of viral and host biomarkers in
virus-associated gynecological cancers